Phase II Study of Bempegaldesleukin (NKTR-214) Together With Palliative Radiation and Anti-PD-1 Checkpoint Blockade in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Bempegaldesleukin (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 11 May 2023 Status changed from active, no longer recruiting to discontinued.
- 09 May 2022 Planned End Date changed from 1 Jun 2026 to 1 Nov 2024.
- 09 May 2022 Planned primary completion date changed from 1 Jun 2024 to 1 Nov 2022.